Ogechi Ikediobi

819 total citations
18 papers, 266 citations indexed

About

Ogechi Ikediobi is a scholar working on Molecular Biology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Ogechi Ikediobi has authored 18 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Infectious Diseases and 3 papers in Pharmacology. Recurrent topics in Ogechi Ikediobi's work include Cancer therapeutics and mechanisms (4 papers), Drug-Induced Adverse Reactions (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Ogechi Ikediobi is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Drug-Induced Adverse Reactions (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Ogechi Ikediobi collaborates with scholars based in United States, South Africa and Poland. Ogechi Ikediobi's co-authors include Louise Warnich, Yuanyuan Xiao, G. Gebhardt, Bradley E. Aouizerat, Monica Gandhi, Narayanasamy Kanikkannan, Madhu Sudhan Shaik, Mandip Singh, John N. Weinstein and Micah S. Ziegler and has published in prestigious journals such as Journal of the American Academy of Dermatology, Clinical Pharmacology & Therapeutics and Molecular Cancer Therapeutics.

In The Last Decade

Ogechi Ikediobi

18 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ogechi Ikediobi United States 9 81 64 60 50 32 18 266
JH Beijnen Netherlands 11 78 1.0× 132 2.1× 91 1.5× 29 0.6× 63 2.0× 15 364
Dung N. Nguyen United States 10 126 1.6× 46 0.7× 37 0.6× 23 0.5× 56 1.8× 25 293
Carla L. Bregman United States 9 79 1.0× 51 0.8× 64 1.1× 12 0.2× 46 1.4× 13 299
Levin Thomas India 10 153 1.9× 101 1.6× 53 0.9× 24 0.5× 10 0.3× 30 364
John Desjardins United States 11 159 2.0× 72 1.1× 42 0.7× 15 0.3× 25 0.8× 13 304
Varun Garg United States 11 94 1.2× 174 2.7× 71 1.2× 47 0.9× 5 0.2× 18 397
Angkana Charoenyingwattana Thailand 9 27 0.3× 21 0.3× 95 1.6× 36 0.7× 74 2.3× 13 311
Casey R. Dorr United States 12 90 1.1× 41 0.6× 59 1.0× 78 1.6× 5 0.2× 29 415
Ralf Winzer Germany 7 121 1.5× 80 1.3× 122 2.0× 10 0.2× 77 2.4× 15 374
Bernd Kost Germany 14 133 1.6× 82 1.3× 50 0.8× 10 0.2× 49 1.5× 30 426

Countries citing papers authored by Ogechi Ikediobi

Since Specialization
Citations

This map shows the geographic impact of Ogechi Ikediobi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ogechi Ikediobi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ogechi Ikediobi more than expected).

Fields of papers citing papers by Ogechi Ikediobi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ogechi Ikediobi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ogechi Ikediobi. The network helps show where Ogechi Ikediobi may publish in the future.

Co-authorship network of co-authors of Ogechi Ikediobi

This figure shows the co-authorship network connecting the top 25 collaborators of Ogechi Ikediobi. A scholar is included among the top collaborators of Ogechi Ikediobi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ogechi Ikediobi. Ogechi Ikediobi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ikediobi, Ogechi, et al.. (2022). 31783 Etanercept in toxic epidermal necrolysis: In support of standard of care. Journal of the American Academy of Dermatology. 87(3). AB56–AB56. 2 indexed citations
2.
Ikediobi, Ogechi, Dawn Z. Eichenfield, & Victoria R. Barrio. (2022). Eosinophilic cellulitis in response to BNT162b2 COVID‐19 vaccination. Pediatric Dermatology. 39(5). 823–824. 8 indexed citations
3.
Ikediobi, Ogechi, et al.. (2021). Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature. Journal of Personalized Medicine. 11(2). 71–71. 5 indexed citations
4.
Ikediobi, Ogechi. (2020). A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics. Clinical Pharmacology & Therapeutics. 110(4). 852–854. 1 indexed citations
5.
Drögemöller, Britt I., Ogechi Ikediobi, Lize van der Merwe, et al.. (2015). CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. AIDS Research and Human Retroviruses. 32(6). 529–538. 16 indexed citations
6.
Ikediobi, Ogechi, et al.. (2015). Familial secondary hyperhidrosis associated with tumor necrosis factor–alpha inhibitor treatment. JAAD Case Reports. 1(6). 418–420. 3 indexed citations
7.
Comfere, Nneka I., Ogechi Ikediobi, Margot S. Peters, Rokea A. el‐Azhary, & Lawrence E. Gibson. (2013). Pharmacogenetics in dermatology: a patient‐centered update. International Journal of Dermatology. 52(8). 1005–1012. 1 indexed citations
8.
Coetzee, Bronwynè, Ashraf Kagee, Mark Tomlinson, Louise Warnich, & Ogechi Ikediobi. (2012). Reactions, Beliefs and Concerns Associated with Providing Hair Specimens for Medical Research among a South African sample: a Qualitative Approach. Future Virology. 7(11). 1135–1142. 17 indexed citations
9.
Walko, Christine M. & Ogechi Ikediobi. (2012). Pharmacogenomic Applications in Oncology. Journal of Pharmacy Practice. 25(4). 439–446. 4 indexed citations
10.
Ikediobi, Ogechi, Bradley E. Aouizerat, Yuanyuan Xiao, et al.. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Human Genomics. 5(4). 265–265. 43 indexed citations
11.
Afable‐Munsuz, Aimee, Ogechi Ikediobi, Mary Beattie, et al.. (2011). Early Developments in Gene-Expression Profiling of Breast Tumors: Potential for Increasing Black–White Patient Disparities in Breast Cancer Outcomes?. Personalized Medicine. 8(6). 669–679. 3 indexed citations
12.
Ikediobi, Ogechi, et al.. (2010). The clinical application of UGT1A1pharmacogenetic testing: Gene-environment interactions. Human Genomics. 4(4). 238–49. 48 indexed citations
13.
Reinhold, William C., Mark A. Reimers, Philip L. Lorenzi, et al.. (2010). Multifactorial Regulation of E-Cadherin Expression: An Integrative Study. Molecular Cancer Therapeutics. 9(1). 1–16. 44 indexed citations
14.
Ikediobi, Ogechi, Mark Reimers, Steffen Durinck, et al.. (2008). In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Molecular Cancer Therapeutics. 7(6). 1337–1346. 11 indexed citations
15.
Ikediobi, Ogechi. (2008). Personalized medicine: are we there yet?. The Pharmacogenomics Journal. 9(2). 85–85. 4 indexed citations
16.
Ikediobi, Ogechi. (2008). Somatic pharmacogenomics in cancer. The Pharmacogenomics Journal. 8(5). 305–314. 20 indexed citations
17.
Shaik, Madhu Sudhan, et al.. (2002). Inhalation Delivery of Anticancer Agents via HFA-Based Metered Dose Inhaler Using Methotrexate as a Model Drug. Journal of Aerosol Medicine. 15(3). 261–270. 18 indexed citations
18.
Shaik, Madhu Sudhan, et al.. (2001). Long-circulating monensin nanoparticles for the potentiation of immunotoxin and anticancer drugs. Journal of Pharmacy and Pharmacology. 53(5). 617–627. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JH Beijnen Breakdown of academic impact, for papers by Dung N. Nguyen Breakdown of academic impact, for papers by Carla L. Bregman Breakdown of academic impact, for papers by Levin Thomas Breakdown of academic impact, for papers by John Desjardins Breakdown of academic impact, for papers by Varun Garg Breakdown of academic impact, for papers by Angkana Charoenyingwattana Breakdown of academic impact, for papers by Casey R. Dorr Breakdown of academic impact, for papers by Ralf Winzer Breakdown of academic impact, for papers by Bernd Kost
Rankless by CCL
2026